That crossover keeps the category culturally aspirational even as it becomes medically mainstream
compositions, combinations, or kits containing active ingredients
Trials moving into neurodegeneration, addiction, inflammation, and beyond
Growth trajectory for the next 3-4 years should be good for a company where on a 3-4 yr basis the company is looking to grow at a 20% CAGR with margins improving as the CMS mix stabilises for the company + scaling up of Peptide business where management is looking to scale it in the similar manner as CMS
Cooper breaks down what's actually happening in your body versus what the internet claims, from bone density concerns to the dreaded "Ozempic face." KEY TAKEAWAYS GLP-1 medications don't cause osteoporosis - inadequate nutrition while losing weight can weaken bones Hair loss is typically from nutritional deficits, not the medication itself These drugs slow gastric emptying but don't cause permanent stomach paralysis Weight regain after stopping is expected since you're treating a chronic medical condition Muscle loss comes from eating too little, not from the medication directly The thyroid cancer warning comes from rodent studies and hasn't been observed in humans GLP-1s actually protect the pancreas rather than damage it NOTABLE QUOTE "Metabolic dysfunction is biological, it's not something within your means to correct just through lifestyle strategies." Dr
)
